EP0789769A2 - Menschliche metallproteinase ihre varianten und dafür kodierende dna-sequenzen - Google Patents

Menschliche metallproteinase ihre varianten und dafür kodierende dna-sequenzen

Info

Publication number
EP0789769A2
EP0789769A2 EP96929420A EP96929420A EP0789769A2 EP 0789769 A2 EP0789769 A2 EP 0789769A2 EP 96929420 A EP96929420 A EP 96929420A EP 96929420 A EP96929420 A EP 96929420A EP 0789769 A2 EP0789769 A2 EP 0789769A2
Authority
EP
European Patent Office
Prior art keywords
metalloproteinase
seq
human
fragment
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96929420A
Other languages
English (en)
French (fr)
Inventor
Andrew James Penrose Docherty
Patrick Marcel Slocombe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9518023.8A external-priority patent/GB9518023D0/en
Priority claimed from GBGB9521495.3A external-priority patent/GB9521495D0/en
Priority claimed from GBGB9521498.7A external-priority patent/GB9521498D0/en
Priority claimed from GBGB9526229.1A external-priority patent/GB9526229D0/en
Priority claimed from GBGB9612150.4A external-priority patent/GB9612150D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of EP0789769A2 publication Critical patent/EP0789769A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a novel human metalloproteinase, to homologues and fragments thereof, to means for producing the metalloproteinase, and to means for regulating its production and activity in vivo.
  • metalloproteinases A number of physiologically important processing events are mediated by metalloproteinases, which under certain circumstances may contribute to pathologies as diverse as inflammation and cancer, and it has been suggested that such enzymes would provide targets for therapeutic intervention. Thus, by varying the production of the enzyme, or inhibiting or enhancing its activity in vivo it should be possible to achieve a therapeutic effect.
  • tumour necrosis factor-alpha is a potent pro ⁇ inflammatory and immunomodulatory mammalian cytokine produced primarily by activated monocytes and macrophages. It is initially expressed as a 233-amino-acid membrane-anchored precursor (pro-TNF- ⁇ ) which is proteolytically processed to yield the mature, 157-amino-acid cytokine.
  • This DNA has the sequence described in SEQ I.D. No: 1 below and may be of use (1) in the production of the metalloproteinase, (2) in the provision of means to regulate the activity of the metalloproteinase in vivo, and (3) in the provision of means to detect and measure a metalloproteinase in a biological system, e.g. in serum, synovial fluid or a tissue extract.
  • nucleotide sequence of SEQ I.D. No: 1 also includes control sequences, such as a polyadenylation sequence, providing for expression of the sequence in a host cell.
  • DNA fragment according to the invention is the isolated human metallo-proteinase-encoding nucleotide sequence of SEQ I.D. No: 2:
  • DNA according to the invention may be obtained using conventional molecular biology procedures, for example by probing a human genomic or cDNA library with one or more labelled oligonucleotide probes containing for example fifteen or more contiguous nucleotides designed using the nucleotide sequences described herein [see for example "Current Protocols in Molecular Biology", Ausubel, F M ef a/(eds ⁇ . Greene Publishing Associates and Wiley-Interscience, New York (1987)].
  • homologue is used herein in relation to a particular nucleotide or amino acid sequence this is to be understood to represent a corresponding sequence in which one or more nucleotides or amino acids have been added, deleted, substituted or otherwise chemically modified, provided always that the homologue retains substantially the same catalytic properties as the particular sequence described.
  • One particular type of homologue for example may be that in which one or more nucleotides have been substituted due to the degeneracy of the genetic code.
  • Homologues may be obtained by standard molecular biology and/or chemistry techniques, e.g.
  • the DNA of SEQ I.D. No: 1 and SEQ I.D. No: 2 each codes for a human metalloproteinase.
  • the DNA according to the invention or a fragment thereof may be used as a probe to screen an appropriate genomic or cDNA library in a process utilising standard hybridisation and/or PCR cloning techniques to obtain the gene or cDNA coding for a homologue or fragment of the metalloproteinase, or a related metalloproteinase from another species.
  • the DNA according to the invention may in turn be used to produce a metalloproteinase.
  • a metalloproteinase in another aspect of the invention we therefore provide an isolated human metalloproteinase which has the amino acid sequence of SEQ I.D. No: 3:
  • the production of a protein according to the invention may be achieved using standard recombinant DNA techniques involving the expression of the metalloproteinase by a host cell.
  • the isolated nucleic acids described herein may be for example introduced into any suitable expression vector by operatively linking the DNA to any necessary expression control elements therein and transforming any suitable procaryotic or eucaryotic host cell with the vector using well known procedures for example as described below in the production of antibodies.
  • the invention is thus to be understood to extend to recombinant plasmids containing a gene of the invention or a nucleotide sequence of SEQ I.D. No: 1 or SEQ I.D. No: 2, to cells containing said recombinant plasmids and to a process for producing the protein according to the invention which comprises culturing said cells such that the desired protein is expressed and recovering the protein from the culture.
  • the nucleotide sequence of SEQ I.D. No: 1 without its 3' poly A tail, or SEQ I.D. No: 2 can be inserted downstream of the hCMV promoter in the pEE12 plasmid vector, and either transiently or stabily expressed in CHO-L761h or NSO mouse melanoma cells [Murphy et al.. J. Biol. Chem.. 267. 9612-9618 (1992)].
  • Expression of the enzyme according to the invention can be detected in serum free culture medium by its catalytic properties, for example as a gelatinolytic band of approximately 58000 kD from CHO cells, by analysis on a gelatin containing polyacrylamide gel [Murphy et al., Biochem. J., 283. 637-641 (1992)].
  • This assay can also be used during the subsequent isolation of the expressed enzyme from transfected cell conditioned medium. If the enzyme requires further activation, this may be achieved proteolytically through use of modest amounts of trypsin, furin, or other methods, in order to remove an approximately 180 amino acid N-terminal propeptide, as described for other metalloproteinases [Murphy et al., J. Biol. Chem., 267.
  • N or C-terminally extended versions of the sequence shown in SEQ I.D. No: 4 may be obtained by expression in procaryotic or eucaryotic cells as described above optionally attached to a peptide tag via which the protein may be affinity purified and identified.
  • tags include the well known "His” or "Strep-tags”.
  • Further sequences that may be attached arise from expression in procaryotic cells and include the pelB or ompA leaders which when placed at the N-terminus help direct secretion to the E.coli periplasmic space [Schmidt and Skerra, J. Chromatography, 676. 337-345 (1994); Knauper et al., J. Biol. Chem., 271, 17124-17131 (1996)].
  • the nucleotide sequences according to the invention may also be of use in diagnosis, for example to determine enzyme deficiency in a human subject, by for example direct DNA sequence comparison or DNA/RNA hybridisation assays; or in therapy, for example where it is desired to modify the production of the metalloproteinase in vivo, and the invention extends to such uses.
  • Knowledge of the gene according to the invention also provides the ability to regulate its activity in vivo by for example the use of antisense DNA or RNA.
  • an antisense DNA or an antisense RNA of a gene coding for a human metalloproteinase said gene containing the nucleotide sequence of SEQ I.D. No: 1 or SEQ I.D. No: 2.
  • the antisense DNA or RNA will correspond to the metalloproteinase gene or a fragment thereof, for example a fragment based on the nucleotide sequence of SEQ I.D. No: 1 or SEQ I.D. No: 2.
  • the antisense DNA or RNA can be produced using conventional means, by standard molecular biology and/or by chemical synthesis as described above. If desired, the antisense DNA and antisense RNA may be chemically modified so as to prevent degradation in vivo or to facilitate passage through a cell membrane, and/or a substance capable of inactivating mRNA, for example ribosyme, may be linked thereto, and the invention extends to such constructs.
  • the antisense DNA or antisense RNA may be of use in the treatment of diseases or disorders in humans in which the over- or unregulated production of the metalloproteinase has been implicated.
  • diseases or disorders may include those described under the general headings of infectious diseases, e.g. HIV infection; inflammatory disease/autoimmunity e.g. rheumatoid arthritis, inflammatory bowel disease; osteoarthritis; cancer; allergic/atopic diseases e.g. asthma, eczema; cardiovascular disease e.g. myocardial infarction, congestive heart failure; systemic inflammatory response syndrome e.g. sepsis syndrome; reperfusion injury; malignancy; cachexia; congenital e.g.
  • cystic fibrosis sickle cell anaemia
  • dermatologic e.g. psoriasis, alopecia
  • neurologic e.g. multiple sclerosis, migraine headache
  • renal e.g. uraemia, nephrotic syndrome
  • obstetric/gynecologic e.g. premature labour, miscarriage, genitourinary prolapse, urinary incontinence, contraception, infertility
  • transplants e.g. organ transplant rejection, graft-versus-host disease
  • metabolic/idiopathic disease e.g. diabetes
  • disorders of the bone such as osteoporosis
  • toxicity e.g. due to chemotherapy, cytokine therapy, and anti-CD3 therapy.
  • the metalloproteinase according to the invention and homologues or fragments thereof may be used to generate substances which selectively bind to the proteins and in so doing regulate the activity of the enzymes.
  • substances include, for example, antibodies, and the invention extends in particular to an antibody which is capable of recognising one or more epitopes on a metalloproteinase containing the amino acid sequence of SEQ I.D. No: 3 or a homologue or fragment thereof.
  • the antibody may be a neutralising antibody.
  • antibody is to be understood to mean a whole antibody or a fragment thereof, for example a F(ab)2, Fab, Fv, VH or VK fragment, a single-chain antibody, a multimeric monospecific antibody or fragment thereof, or a bi- or multispecific antibody or fragment thereof.
  • the antibody according to the invention may be a polyclonal or, especially, a monoclonal antibody.
  • the antibody may belong to any immunoglobulin class, and may be for example an IgG, for example IgG-i, lgG2. lgG,3 lgG4, IgE, IgM or IgA antibody. It may be of animal, for example mammalian origin, and may be for example a murine, rat or human antibody. Alternatively, the antibody may be a chimeric antibody.
  • the term chimeric antibody is used herein to mean any antibody containing portions derived from different animal species.
  • Particular examples include those antibodies having a variable region derived from a murine or other antibody constant region, and those antibodies in which one or more CDR sequences and optionally one or more variable region framework amino acids are derived from a murine or other antibody and the remaining portions of the variable and the constant regions are derived from a human immunoglobulin.
  • Antibodies according to the invention may be prepared by conventional immunisation and recombinant DNA techniques.
  • polyclonal antibodies may be obtained from the sera of animals immunised with a metalloproteinase according to the invention or a homologue or fragment thereof.
  • Any suitable host for example BALB/c mice where it is desired to obtain a mouse polyclonal antibody, may be injected with the immunogen, the serum collected and the antibody recovered therefrom.
  • Monoclonal antibodies may be obtained from hybridomas derived from the spleen cells of an animal immunised as just discussed and fused to an appropriate "immortal" B-tumour cell.
  • the antibody may be recovered from either the serum or the hybridoma by making use of standard purification and or concentration techniques, for example by chromatography, using for example Protein A or by other affinity chromatography employing a metalloproteinase of the invention or a homologue or fragment thereof.
  • a cell line for example a hybridoma, expressing an antibody according to the invention
  • other chimeric antibodies according to the invention may be obtained by preparing one or more replicable expression vectors containing at least the DNA sequence encoding the variable domain of the antibody heavy or light chain and optionally other DNA sequences encoding remaining portions of the heavy and/or light chains as desired, and transforming an appropriate cell line, e.g. a non-producing myeloma cell line, such as a mouse NSO line, in which production of the antibody will occur.
  • an appropriate cell line e.g. a non-producing myeloma cell line, such as a mouse NSO line
  • the DNA sequence in each vector should include appropriate regulatory sequences, particularly a promoter and leader sequence operably linked to the variable domain sequence.
  • appropriate regulatory sequences particularly a promoter and leader sequence operably linked to the variable domain sequence.
  • Particular methods for producing antibodies in this way are generally well known and routinely used. For example, basic molecular biology procedures are described by Maniatis et al [Molecular Cloning, Cold Spring Harbor Laboratory, New York, 1989]; DNA sequencing can be performed as described in Sanger et al [PNAS 74. 5463, (1977)] and the Amersham International pic sequencing handbook; and site directed mutagenesis can be carried out according to the method of Kramer et al [Nucl. Acids Res. 12, 9441 , (1984)] and the Cambridge Biotechnology Ltd handbook.
  • Antibodies and other selective binding agents according to the invention may be of use in therapy, either alone or as a delivery agent, for the delivery of a drug, prodrug, radiometal or radioisotope, for example in the treatment of diseases such as those described above in humans and/or other animals, or may find a use as purification agents in the preparation of the human metalloproteinase or homologues or fragments thereof.
  • selective binding agents of the invention may form the basis of a diagnostic assay to detect the presence or absence in a biological sample (e.g. serum, synovial fluid or a tissue extract) of a metalloproteinase as described herein.
  • a biological sample e.g. serum, synovial fluid or a tissue extract
  • the binding agent may be brought into contact with a sample of serum, synovial fluid or tissue under conditions in which a complex is formed between the binding agent and target metalloproteinase.
  • Qualitative and/or quantitative detection of the complex can then be used to determine the presence or absence of the metalloproteinase and in particular whether the enzyme is present in an abnormal quantity associated for example with a particular disease state.
  • the metalloproteinases according to the invention may in particular be used to screen for compounds which regulate the activity of the enzymes and the invention extends to such a screen and to the use of compounds obtainable therefrom to regulate metalloproteinases in vivo.
  • a process for obtaining a compound capable of regulating the action of a human metalloproteinase in vivo which comprises subjecting one or more test compounds to a screen comprising (A) a metalloproteinase having the amino acid sequence of SEQ I.D. No: 3 or a homologue or fragment thereof, or (B) a host cell transformed to be capable of expressing a nucleotide sequence of SEQ I.D. No: 1 or SEQ I.D. No: 2 or a homologue or fragment thereof.
  • the screen according the invention may be operated using conventional procedures, for example by bringing the test compound or compounds to be screened and an appropriate substrate into contact with the metalloproteinase or a cell capable of producing it and determining affinity for the protein in accordance with standard practice.
  • any compound obtainable in this way may have a potential use in the treatment in humans and/or other animals of one or more of the above mentioned diseases.
  • the invention thus extends to a compound selected through its ability to regulate the activity of a metalloproteinase in vivo as primarily determined in a screening assay utilising a metalloproteinase having an amino acid sequence of SEQ I.D. No: 3 or a homologue or fragment thereof or a gene coding therefor, for use in the treatment of a disease in which the over- or under-activity or unregulated activity of the metalloproteinase is implicated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP96929420A 1995-09-05 1996-09-05 Menschliche metallproteinase ihre varianten und dafür kodierende dna-sequenzen Withdrawn EP0789769A2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9518023.8A GB9518023D0 (en) 1995-09-05 1995-09-05 Biological compounds
GB9518023 1995-09-05
GBGB9521495.3A GB9521495D0 (en) 1995-10-20 1995-10-20 Biological compounds
GB9521495 1995-10-20
GB9521498 1995-10-20
GBGB9521498.7A GB9521498D0 (en) 1995-10-20 1995-10-20 Biological compounds
GBGB9526229.1A GB9526229D0 (en) 1995-12-21 1995-12-21 Biological compounds
GB9526229 1995-12-21
GB9612150 1996-06-11
GBGB9612150.4A GB9612150D0 (en) 1996-06-11 1996-06-11 Biological compounds
PCT/GB1996/002181 WO1997009430A2 (en) 1995-09-05 1996-09-05 A human metalloproteinase, variants thereof and dna sequences codding therefor

Publications (1)

Publication Number Publication Date
EP0789769A2 true EP0789769A2 (de) 1997-08-20

Family

ID=27517310

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96929420A Withdrawn EP0789769A2 (de) 1995-09-05 1996-09-05 Menschliche metallproteinase ihre varianten und dafür kodierende dna-sequenzen

Country Status (3)

Country Link
EP (1) EP0789769A2 (de)
AU (1) AU6883396A (de)
WO (1) WO1997009430A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1111047A4 (de) 1998-09-03 2002-10-02 Takeda Chemical Industries Ltd Protein und dessen dns
DE10238298A1 (de) * 2002-08-21 2004-03-04 Beiersdorf Ag Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
WO2008119882A2 (en) * 2007-03-30 2008-10-09 Wallac Oy Screening methods based on human adam12 polypeptide and binding agents thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATRISIAN L.M.: "Metalloproteinases and their inhibitors in matrix remodelling", TREND IN GENETICS, vol. 6, no. 4, 1 April 1990 (1990-04-01), pages 121 - 125 *

Also Published As

Publication number Publication date
WO1997009430A3 (en) 1997-05-01
AU6883396A (en) 1997-03-27
WO1997009430A2 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
US6225103B1 (en) Cloning and characterization of napsin
Yazaki et al. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications
AU2008202992B2 (en) Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same
CN104854133B (zh) 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
US5883241A (en) DNA sequences coding for a human metalloproteinase and variants thereof
WO1998022597A9 (en) Cloning and characterization of napsin, an aspartic protease
JPH05506580A (ja) ウォーク―スルー突然変異誘発
JPS62272990A (ja) リガンド、そのアンタゴニストまたはアゴニストの効率的な測定のためのハイブリツドリセプタ−
JPH05503430A (ja) 完全合成アフィニティ試薬
US6753176B2 (en) Aggrecan degrading metallo proteases
CN109384843B (zh) 抗体及其制造方法、以及提升抗体的热稳定性的方法
JP3504963B2 (ja) 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
EP0789769A2 (de) Menschliche metallproteinase ihre varianten und dafür kodierende dna-sequenzen
Kobayashi et al. Specificities and rates of binding of anti-(6–4) photoproduct antibody fragments to synthetic thymine photoproducts
US5990293A (en) Human metalloproteinase, variants thereof and DNA sequence coding therefor
CN116143917B (zh) 一种抗d-二聚体的抗体及其制备方法和用途
US20020169127A1 (en) Compositions and methods for diagnosing or treating psoriasis
Gulliver et al. Conversion of an anti-single-stranded DNA active site to an anti-fluorescein active site through heavy chain complementarity determining region transplantation.
Pajunen et al. Cloning, sequencing, expression and characterization of three anti-estradiol-17β Fab fragments
JP2003235556A (ja) 抗ヒトキマーゼモノクローナル抗体およびそれらの利用
CN113173992B (zh) 一种白细胞抗原结合多肽
US5196526A (en) CDNA clone for T-cell suppressor inducer factor
CA2350227A1 (en) Novel serine protease bssp5
JP2811086B2 (ja) ネコ×マウスヘテロハイブリドーマおよびネコ免疫グロブリンλ鎖の定常領域をコードする遺伝子断片
CN118043349A (zh) 一种人源化抗人GPVI单克隆抗体Fab片段及其应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970521

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): CH DE FR GB LI

17Q First examination report despatched

Effective date: 20010430

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010911